Younger patients with relapsed MDS may benefit from DLI post-stem cell transplant, improving overall survival rates. DLI is associated with graft-versus-host disease, but its impact on prognosis is ...

Please provide your email address to receive an email when new articles are posted on . Olutasidenib monotherapy or combination therapy may help certain patients with myelodysplastic syndrome achieve ...

In-hospital outcomes of patients with myelodysplastic syndromes and rheumatic heart disease: A National Inpatient Sample study (2018-2020). Association between ferritin, hemoglobin, and anemia ...

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS Genetic testing for hereditary cancer unexpectedly uncovers a case of myelodysplastic syndrome (MDS), highlighting the need ...

BACKGROUND. Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms with variable clinical outcomes and an increased risk of progression to Acute Myeloid Leukemia (AML). Given ...

Serial post-transplant chimerism assessment provided more reliable prognostic insight than a single early measurement.

MILAN — Immune-based treatments continue to fall short in myelodysplastic syndromes (MDS). Now, experts from the European Hematology Association’s (EHA) Specialized Working Group on MDS here at the ...